# Nicoletta Colombo

Source: https://onco.cc/people/nicoletta-colombo/  
OnCo record `nicoletta-colombo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer.

## Summary

Nicoletta Colombo was principal investigator of KEYNOTE-826, which showed pembrolizumab added to chemotherapy with or without bevacizumab improves survival in persistent, recurrent or metastatic cervical cancer, the first immunotherapy survival gain in the disease. She has chaired ESMO-ESGO ovarian cancer consensus conferences and led MITO and ENGOT trials. She directs gynaecologic oncology at IEO.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cervical; immunotherapy; guidelines
- Role: Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca
- Specialisms: Cervical cancer; Ovarian cancer; Immunotherapy; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Colombo%20N%5BAuthor%5D%20cervical%20pembrolizumab

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [European Society of Gynaecological Oncology](https://onco.cc/institutions/esgo/), [IEO (European Institute of Oncology)](https://onco.cc/institutions/ieo-milan/)
- trials: [KEYNOTE-826](https://onco.cc/trials/keynote-826/)

---
JSON: https://onco.cc/api/v1/entities/nicoletta-colombo.json